HAVN Life Sciences (5NP0) Stock Statistics & Valuation Metrics
Total Valuation
HAVN Life Sciences has a market cap or net worth of EUR 491.57K. The enterprise value is EUR 449.37K.
- Market Cap
- EUR 491.57K
- Enterprise Value
- EUR 449.37K
Share Statistics
HAVN Life Sciences has 25,646,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 25,646,020
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
HAVN Life Sciences’s return on equity (ROE) is -2.30 and return on invested capital (ROIC) is -222.27%.
- Return on Equity (ROE)
- -2.30
- Return on Assets (ROA)
- -2.13
- Return on Invested Capital (ROIC)
- -222.27%
- Return on Capital Employed (ROCE)
- -2.24
- Revenue Per Employee
- 46.08K
- Profits Per Employee
- -3.74M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 12.82
Valuation Ratios
The current PE Ratio of HAVN Life Sciences is -0.01. HAVN Life Sciences’s PEG ratio is 0.00.
- PE Ratio
- -0.01
- PS Ratio
- 4.17
- PB Ratio
- 0.04
- Price to FCF
- -0.14
- Price to Operating Cash Flow
- -0.02
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, HAVN Life Sciences had revenue of 276.47K and earned -22.44M in profits. Earnings per share was -5.25.
- Revenue
- 276.47K
- Gross Profit
- 89.69K
- Operating Income
- -9.81M
- Pretax Income
- -22.44M
- Net Income
- -22.44M
- EBITDA
- -21.80M
- Earnings Per Share (EPS)
- -5.25
Cash Flow
In the last 12 months, operating cash flow was -2.61M and capital expenditures 7, giving a free cash flow of -2.61M billion.
- Operating Cash Flow
- -2.61M
- Free Cash Flow
- -2.61M
- Free Cash Flow per Share
- -1.86
Dividends & Yields
HAVN Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -691.30%
- Earnings Yield
- -17484.06%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
HAVN Life Sciences upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Dec 20, 2024
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
HAVN Life Sciences as a current ratio of 14.84, with Debt / Equity ratio of 3.46%
- Current Ratio
- 14.84
- Quick Ratio
- 14.34
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.35
- Interest Coverage Ratio
- -1734.96
Taxes
In the past 12 months, HAVN Life Sciences has paid 64.14K in taxes.
- Income Tax
- 64.14K
- Effective Tax Rate
- -0.00
Enterprise Valuation
HAVN Life Sciences EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.06.
- EV to Sales
- 1.76
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.06
- EV to Operating Cash Flow
- -0.06
Balance Sheet
HAVN Life Sciences has EUR 13.99K in cash and marketable securities with EUR 26.23K in debt, giving a net cash position of -EUR 12.25K billion.
- Cash & Marketable Securities
- EUR 13.99K
- Total Debt
- EUR 26.23K
- Net Cash
- -EUR 12.25K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.09
Margins
Gross margin is 32.44%, with operating margin of -3548.44%, and net profit margin of -8117.81%.
- Gross Margin
- 32.44%
- Operating Margin
- -3548.44%
- Pretax Margin
- -8117.81%
- Net Profit Margin
- -8117.81%
- EBITDA Margin
- -7886.41%
- EBIT Margin
- -8094.61%
